Developing a new treatment targeting LCN2 for lung cancer
Official title: Targeting LCN2, a novel therapy for lung cancer
Funded at New York University School of Medicine · NIH-11040380 · Data updated 2026-11-12
This study is looking at a new way to help people with KRAS-driven non-small cell lung cancer by targeting a protein called Lipocalin 2, which might help tumors hide from the immune system, to see if we can make current treatments work better and improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 3, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $696,569 |
| NIH project number | 1R01CA297605-01 |
| Project ID | NIH-11040380 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with KRAS-driven non-small cell lung cancer who have not responded well to standard therapies.
✕Less likely to help
Patients with lung cancer that does not have KRAS mutations or those who have already responded well to existing treatments may not benefit from this research.
What this research studies
This research focuses on a novel therapy for KRAS-driven non-small cell lung cancer (NSCLC), which is known for its aggressive nature and resistance to standard treatments. The study investigates the role of Lipocalin 2 (LCN2), a protein that may help tumors evade the immune system, and aims to develop strategies to inhibit its effects. By using advanced techniques like CRISPR/Cas9, researchers will explore how targeting LCN2 can enhance the effectiveness of existing cancer therapies and improve patient outcomes. The goal is to identify new treatment options that can work alongside current therapies to better combat this challenging form of lung cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KRAS-driven lung cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in targeting immunomodulatory molecules like LCN2, suggesting that this approach could be a viable new strategy in cancer treatment.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Papagiannakopoulos, Thales — New York University School of Medicine
- Study coordinator: Papagiannakopoulos, Thales
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.